EBSEmergent BioSolutions Inc.

Healthcare

$6.81-31% 1Y

$6.81

$4.4552 weeks$13.90

Is the price fair?

Good

Undemanding: modest expectations priced in and cheap against its own history.

2 good, 1 without data

What the price assumes~−17% a yearderived · Jun 30, 2026

Priced for a decline (~−17% a year). The price bakes in little to no growth.

Vs its own P/E rangecheaper than 77% of its own historyderived

Cheap vs its own history: P/E 13.4 vs a 23.6 median over 26 quarters (−43% vs median).

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What EBS's price assumes

Emergent BioSolutions Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 0.66× revenue.

0.66

Price / sales · no P/E: the last twelve months did not end in a profit

Free cash flow yield: 24%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.9%
Growth the price implies: −17%
Growth the price implies · What free cash flow would have to do every year for a decade to justify today's price, discounted at 9.0%.
Price / book: 0.82
Price / book · as of 2026-Q1